Introduction {#section1-1352458515572406}
============

Neuromyelitis optica (NMO) is an autoimmune inflammatory disorder of the central nervous system that predominantly targets the optic nerve and spinal cord. Until recently, NMO was thought to be a clinical variant of multiple sclerosis (MS). However, clinical features, neuroimaging, immunological, and histopathological characteristics have now been identified which distinguish NMO from MS. Clifford and Gault summarized the salient features of the disease in 1894, though descriptions of the disease appeared much earlier. The typically long spinal cord segmental involvement, longitudinally extensive transverse myelitis (LETM) and neutrophilic pleocytosis in the cerebrospinal fluid (CSF) became incorporated into the first Wingerchuk diagnostic criteria for NMO in 1999.^[@bibr1-1352458515572406]^ Subsequently, the discovery of anti AQP4-IgG^[@bibr2-1352458515572406]^ led to the revised Wingerchuk criteria in 2006.^[@bibr3-1352458515572406]^ The term "NMO spectrum disorders"^[@bibr4-1352458515572406]^ (NMOSD) encompasses forms of NMO that do not satisfy the 2006 criteria. Examples include isolated unilateral or simultaneous bilateral or recurrent optic neuritis (ON); isolated or recurrent transverse myelitis (TM); typical NMO brain lesions (hypothalamus, corpus callosum, brainstem, periventricular) with or without detectable anti AQP4-IgG autoantibody. Thus, the diagnostic criteria have been refined and the spectrum of clinical manifestations in NMO has expanded in recent years.

NMO occurs worldwide in diverse races and cultures; however, the global incidence and prevalence of this disease is incompletely characterized. More specifically, it is unclear whether disease frequency, clinical course, severity, and gender predominance vary between geographical regions. Obtaining epidemiological and demographic data for a relatively uncommon disorder like NMO is challenging. Very few published reports of NMO have appeared from emerging nations. Access to magnetic resonance imaging (MRI) centers varies, as do laboratory facilities for CSF analysis and anti AQP4-IgG detection. Hence, timing of the MRI after an attack of myelitis and blood sampling for anti AQP4-IgG testing may vary. Furthermore, lack of uniformity of survey methods, disease definitions, and diagnostic criteria complicate interpretation of the literature.

A small proportion of patients with NMO are seronegative for anti AQP4-IgG, and may represent a heterogeneous spectrum of NMO or disease mimics (including MS and other diseases such as sarcoidosis and paraneoplastic disorders). Thus, studies that include all clinically defined NMO patients are difficult to compare with those selecting only anti AQP4-IgG-positive patients. In addition, assays for detection of anti AQP4-IgG vary with regard to their sensitivity and specificity. Although most contemporary assays perform well in a high-probability patient, when used for population screening the seropositive rate can vary by two-fold or greater between assays of different specificity.^[@bibr5-1352458515572406],[@bibr6-1352458515572406]^ The initial AQP4-IgG immunofluorescence assay that was developed is the least sensitive.^[@bibr2-1352458515572406],[@bibr6-1352458515572406]^ The cell-based assay (CBA), although labor intensive and less suited to mass screening, is most sensitive and specific for use in clinical diagnosis.^[@bibr6-1352458515572406],[@bibr7-1352458515572406]^ Thus, differences in diagnostic criteria and anti AQP4-IgG assays may account for heterogeneity in epidemiologic data, and may explain some of the observed discrepancies in interpretation.

The goal of this review article is to assess major epidemiological and hospital-based studies to estimate incidence and prevalence of NMO in different geographic regions, and to provide insights into the differences and similarities of demographic and clinical features of NMO among diverse populations.

Methods {#section2-1352458515572406}
=======

In this paper, we reviewed the published reports of population-based studies, hospital-based retrospective chart reviews, and data from NMO registries. We queried the PubMed database from the years 1999--2014. The search terms used included "neuromyelitis optica", "Devic's disease", "incidence", "prevalence", "epidemiology", "demography" and "clinical features". In total, 48 studies were examined. Of these, seven population-based epidemiological studies ([Table 1](#table1-1352458515572406){ref-type="table"}) and nine hospital-based studies were included for comparative analysis of clinical and demographic features ([Table 2](#table2-1352458515572406){ref-type="table"}). All studies that were included had utilized Wingerchuck 1999 or 2006 criteria, and results of anti AQP4 - IgG testing were available. Lastly, to integrate a global demographic perspective, selected data obtained from the Atlas of MS 2013 ([www.atlasofms.org](http://www.atlasofms.org)) were also included in the analysis.

###### 

Comparative Incidence and prevalence of NMO from recently published studies.

  Country                                                                 Diagnostic criteria     Source of data                                                                                        No of cases/population at risk   Ethnicity                          Crude incidence/100,000   Crude prevalence/100,000   F/M
  ----------------------------------------------------------------------- ----------------------- ----------------------------------------------------------------------------------------------------- -------------------------------- ---------------------------------- ------------------------- -------------------------- ------------
  French West Indies Cabre et al.,^[@bibr9-1352458515572406]^ 2007/2009   Wingerchuk 1999, 2006   Hospitals, clinics, neurologists, other specialists, registry, patient association                    20/ 683,000                      Afro-Caribbean Hispanic            0.19 (0.15--0.23)         2.53                       All female
  Cuba Cabrera Gomez et al.,^[@bibr10-1352458515572406]^ 2009             Wingerchuk 1999         Hospitals, clinics, other specialists, neurologists, clinical trial data, MS data base, media         11/11,177,743                    Caucasian Afro-Caribbean           0.053 (0.04--0.07)        0.54 (0.39--0.69)          7.3:1
  Denmark Asgari et al.,^[@bibr8-1352458515572406]^ 2011                  Wingerchuk 2006         National Registry, Hospitals, MS-clinics, neurologists, other specialists, administrative databases   42/952,000 NMO=36, NMOSD=6       99% Caucasian                      0.04                      4 (3.1--5.7)               2.8:1
  Wales Cossburn et al.,^[@bibr13-1352458515572406]^ 2012                 Wingerchuk 2006         Hospital records, Neurologists, Regional database, Lab records                                        14/717,572 NMO=11, NMOSD=3       100% Caucasian                     --                        1.96 (1.22--2.97)          6:1
  Japan Houzen et al.,^[@bibr14-1352458515572406]^ 2012                   Wingerchuk 2006         Inpatient and outpatient records of MS-related institutions                                           3/352,353                        Japanese                           NA                        0.9 (0.2--2.5)             All female
  UK Jacob et al.,^[@bibr11-1352458515572406]^ 2013                       Wingerchuk 2006         Hospital records, regional general hospital records, lab records                                      8/1,145,322 NMO=5 NMOSD=3        Caucasian 7 (88%) African 1(12%)   0.08 (0.03--0.16)         0.72 (0.3--0.16)           3.5:1
  India Pandit et al.,^[@bibr15-1352458515572406]^ 2014                   Wingerchuk 2006         Disease registry, inpatient and outpatient records of teaching hospitals and clinics, MRI centers     11/ 419,306                      South Indians                      NA                        2.6                        1.2:1

###### 

Clinical and demographic features of NMO^[\#](#table-fn3-1352458515572406){ref-type="table-fn"}^.

  Country/ study                                                          Wingerchuk diagnostic criteria   Cases selected   Total cases & gender (F/M)   Ethnicity                 Mean Age at onset & range   Median time to 1^st^ relapse (months)   First attack                   AQP4[\*](#table-fn2-1352458515572406){ref-type="table-fn"} IgG +ve   Median follow-up        Median EDSS     Mortality disease related
  ----------------------------------------------------------------------- -------------------------------- ---------------- ---------------------------- ------------------------- --------------------------- --------------------------------------- ------------------------------ -------------------------------------------------------------------- ----------------------- --------------- ---------------------------
  French West Indies Cabre et al.,^[@bibr9-1352458515572406]^ 2007/2009   Wingerchuk 1999, 2006            NMO              96 (88F/8M)                  Hispanic Afro-Caribbean   29.5 (11--74)               11.5 (1--300)                           NA                             32%                                                                  9.5 (1--40) years       NA              24 (25%)
  Brazil Bichuetti,^[@bibr20-1352458515572406]^ 2009                      1999, 2006                       NMO relapsing    41 (29F/ 12M)                NA                        32.6 (20--60)               NA                                      TM 41% ON34%ON+TM 24%          41%                                                                  52 (7--200) months      NA              4 (14.3%)
  France Collongues et a1.,^[@bibr16-1352458515572406]^ 2010              2006                             NMO, NMOSD       125 (94F/31M)                White=87% other=13%       34.7 (4--66)                12 (30.8--43.1)                         TM 45.6% ON 36.8%              54%                                                                  8.7 (0.1--39.5) years   NA              4 (3.2%)
  Denmark Asgari et al.,^[@bibr8-1352458515572406]^ 2011                  2006                             NMO NMOSD        42 (31F/11M)                 White=99%                 35.6 (15--64)               NA                                      TM 59.5% ON 35.7%              62.0%                                                                6.5 (2--10) years       6.5 (1.0--9)    3 (7.1%)
  Germany Jarius et al.,^[@bibr17-1352458515572406]^ 2012                 2006                             NMO, NMOSD       175 (150F/25M)               White =100%               39 (10-81)                  8.5 (1--216)                            ON 58% ON+TM 8 %               78.3%                                                                4.8 (0--390) months     6.5 (1.5--10)   5 (2.9%)
  USA Mealy et al.,^[@bibr19-1352458515572406]^ 2012                      2006                             NMO, NMOSD       187(162F/25M)                White=89 AA=69 other=29   40                          NA                                      TM 50.2% ON 35.3%              66.6%                                                                5.5 (0.2--38) months    NA              NA
  Korea Kim et al.,^[@bibr22-1352458515572406]^ 2012                      2006                             NMO, NMOSD       106 (97F/9M)                 Korean=100%               NA                          5 (1--74)                               NA                             100%                                                                 7.0 (1--24) years       NA              NA
  India Pandit et al.,^[@bibr21-1352458515572406]^ 2013                   2006                             NMO, NMOSD       70(30F/40M                   South Indians-100%        37.5 (12--65)               12 (4--96)                              NA                             39%                                                                  4.5 (1--13) years       5.5 (1.5--10)   12 (17%)
  Austria Aboul-Enein et al.,^[@bibr12-1352458515572406]^ 2013            1999, 2006 (all seropositive )   NMO, NMOSD       73 (63/10)                   White=100%                45.7 (12.3--79.6)           NA                                      ON 54.2% TM 41.7% ON+TM 4.2%   97% (71/73)                                                          NA                      NA              NA
  Spain Höftberger et al.,^[@bibr18-1352458515572406]^ 2014               2006                             NMO              48 (41F/7M)                  White=94% Other=6%        38 (18--73.5)               8.3 (1--144)                            TM 36%; ON 29%; ON+TM 33%      81%                                                                  69 (1--415) months      3.8 (0--10)     2 (4.2%)

AF: African; AS: Asian; AA: African American; ON: optic neuritis; TM: transverse myelitis; ARR: annualized relapse rate; NA: not available.

percentage of patients who were AQP4-IgG positive among those tested.

Used either Wingerchuk 1999 or 2006 criteria, all others used Wingerchuk 2006 alone.

Population-based studies {#section3-1352458515572406}
========================

While data from population-based studies are likely to be more robust, several factors make direct comparisons across such studies challenging. For example, variability in the source data (e.g. clinic, health insurance data, or population based), diagnostic criteria, inclusion of seronegative individuals, definition of NMOSD, and the particular anti AQP4-IgG assay used are important factors undoubtedly influencing the results. The ethnic mix of the populations studied may also influence the prevalence rates. In addition, most published studies have focused on adults.

Incidence {#section4-1352458515572406}
=========

There have been several recent studies from Denmark, West Indies, Cuba, the UK, and Austria from which unadjusted incidence rates (per 100,000) could be calculated ([Table 1](#table1-1352458515572406){ref-type="table"}).^[@bibr8-1352458515572406][@bibr9-1352458515572406][@bibr10-1352458515572406][@bibr11-1352458515572406]--[@bibr12-1352458515572406]^ In a Danish population comprising 99% whites, an incidence rate of 0.40 (95%CI 0.30--0.54) was found to be the highest among the five studies included.^[@bibr8-1352458515572406]^ A French West Indies study^[@bibr9-1352458515572406]^ found that the age and sex-standardized incidence was 0.22 (95%CI 0.04--0.38), and remained consistent between 1992 and 2007. While the latter study included only NMO cases in which Wingerchuk criteria were fully met, the Danish study included all individuals carrying the diagnosis of NMO, regardless of whether they met these criteria. Thus, selection criteria may influence incidence rates of the disease. A Cuban study included white subjects of Spanish descent, African, and those of mixed racial origins.^[@bibr10-1352458515572406]^ Here, an overall incidence rate of 0.05 was observed, and was similar across ethnic groups, but varied from 0.12--1.76 across geographical regions of Cuba. The incidence rate in Merseyside, UK, a population consisting of 88% whites, was found to be 0.08 (95%CI 0.03--0.16).^[@bibr11-1352458515572406]^ An Austrian study^[@bibr12-1352458515572406]^ reported an incidence rate of 0.05 (95% CI 0.01--0.31), in an all-white population.

Prevalence {#section5-1352458515572406}
==========

Several studies have measured prevalence (per 100,000) in NMO. The prevalence was 4.4 in Denmark^[@bibr8-1352458515572406]^ (95%CI 3.1--5.7), 1.96 among the white population of Wales,^[@bibr13-1352458515572406]^ 0.72 in Merseyside, UK,^[@bibr11-1352458515572406]^ 2.3 in the French West Indies^[@bibr9-1352458515572406]^ and 0.52^[@bibr10-1352458515572406]^ in Cuba. The vast majority of patients in an NMOSD cohort in Austria^[@bibr12-1352458515572406]^ (71/73, all whites) were seropositive. The prevalence rate of NMO was 0.77 per 100,000.^[@bibr12-1352458515572406]^ Prevalence data are also available from Japan and India. In Japan, a prevalence rate of 0.9 per 100,000 (95%CI 0.2--2.5) was determined,^[@bibr14-1352458515572406]^ while in southern India it was 2.7/100,000.^[@bibr15-1352458515572406]^ Collectively, these studies suggest a relatively wide range in prevalence, including differences in geographic and ethnic cohorts. The Danish study was the only one that included limited forms of NMO.

Hospital-based studies {#section6-1352458515572406}
======================

Nine hospital-based observational studies were identified ([Table 2](#table2-1352458515572406){ref-type="table"}), four from Europe,^[@bibr12-1352458515572406],[@bibr16-1352458515572406][@bibr17-1352458515572406]--[@bibr18-1352458515572406]^ one each from the USA,^[@bibr19-1352458515572406]^ Brazil,^[@bibr20-1352458515572406]^ Austria,^[@bibr12-1352458515572406]^ India,^[@bibr21-1352458515572406]^ and Korea.^[@bibr22-1352458515572406]^ All of these studies used Wingerchuk 2006 diagnostic criteria except the Spanish^[@bibr18-1352458515572406]^ study (which used 1999 and 2006 criteria). Median time to second attack was 8--12 months (range 1--216 months). Mortality ranged from 2.9--25% and was disease related in the majority of cases. Analysis of registry-based data suggests that the proportion of patients with NMO among all demyelinating disorders varies significantly among different geographic regions: 1.2% in Italy,^[@bibr23-1352458515572406]^ 1--2% in the USA,^[@bibr19-1352458515572406]^ 13.7% in India,^[@bibr21-1352458515572406]^ and 39.3% in Thailand.^[@bibr24-1352458515572406]^ The study from Thailand underscores the need for supportive radiological criteria that justify the clinical diagnosis. Several anti AQP4-IgG seropositive patients with a diagnosis of MS, in retrospect had radiological and clinical features of NMO.

Effect of age {#section7-1352458515572406}
=============

There are geographic differences with respect to NMO and patient age. From prevalence studies, median age at onset was found to be 30.5 years in Cuba,^[@bibr10-1352458515572406]^ 39.5 years in South East Wales,^[@bibr13-1352458515572406]^ 30 years in Denmark,^[@bibr8-1352458515572406]^ and 55.2 years in Austria.^[@bibr12-1352458515572406]^ These differences may reflect variations in case ascertainment and diagnostic criteria, access to medical care, and/or ethnicity. In the Cuban study, blacks were older than non-blacks at disease onset; however, there were no differences between other subgroups.^[@bibr10-1352458515572406]^ The mean age of onset of NMO ranged from 32.6--45.7 years in major case series ([Table 2](#table2-1352458515572406){ref-type="table"}). In a study comparing seropositive individuals (based on the CBA) in the UK, and Japan, Afro-Caribbeans experienced earlier disease onset than white and Asian patients.^[@bibr24-1352458515572406]^ Pediatric onset is rare, with \<5% of cases presenting prior to age 18 in two studies.^[@bibr25-1352458515572406],[@bibr26-1352458515572406]^ In contrast, late-onset NMO/NMOSD, defined as onset age \>50 years, accounted for 108/430 (25%) in a large multicenter cohort study.^[@bibr27-1352458515572406]^ Compared with patients with adult-onset NMO, those with pediatric NMO more frequently have brain involvement, experience milder locomotor disability, and develop significantly earlier visual disability.^[@bibr25-1352458515572406]^ In a German study that contrasted clinical presentation of seropositive and negative NMO patients, the proportion of anti-AQP4-IgG-positive patients appeared to increase with age; however, mean age at onset did not differ among seronegative and seropositive patients.^[@bibr17-1352458515572406]^ The largest study assessing serological status and age is that from the Mayo clinic, which compared the demographics of over 50,000 patients referred for NMO-IgG testing.^[@bibr26-1352458515572406]^ Similar to the German study,^[@bibr17-1352458515572406]^ the proportion of seropositive females was shown to increase with age, and was highest in the \>65 year-old group, accounting for 12% of the entire seropositive cohort.

Gender ratio {#section8-1352458515572406}
============

As with many autoimmune diseases, NMO and NMOSD are more common in females, ranging from 66--88% of the patient population.^[@bibr8-1352458515572406],[@bibr9-1352458515572406],[@bibr16-1352458515572406]^ One study reported an 89% female predominance when including only cases with relapsing NMO. Even prior to the discovery of anti AQP4-IgG, relapsing NMO was known to be more prevalent in females (83%), whereas a more equal female/male distribution was detected in monophasic disease (48%). Anti AQP4-IgG positivity was associated with relapsing disease with rates of 81--91%,^[@bibr17-1352458515572406],[@bibr28-1352458515572406]^ particularly when CBA is used. Among patients with LETM, females represent 86% of anti AQP4-IgG seropositive compared with 44% of seronegative individuals.^[@bibr29-1352458515572406]^ The variation across studies may be influenced by limited patient numbers in those conducted within specialized centers. Moreover, there may be racial and geographical effects. For example, in a comparative study from different populations^[@bibr24-1352458515572406]^ females represented 82% of patients in whites from the UK, compared with 75% in Afro-Caribbeans and 98% in a Japanese cohort. In an all-white Austrian cohort, the female ratio was 87% for all AQP4-IgG-positive patients^[@bibr12-1352458515572406]^ while it reached 100% in a French West Indian cohort.

Disease onset, course and severity {#section9-1352458515572406}
==================================

Several multicenter registry-based observational, retrospective studies ([Table 2](#table2-1352458515572406){ref-type="table"}) provide information about clinical course and disease severity. Some common findings emerged from these studies. The presenting symptom was usually either ON or TM, especially among seropositive patients. Simultaneous TM and ON, bilateral ON, and monophasic course were relatively more common presentations among seronegative patients.^[@bibr16-1352458515572406],[@bibr17-1352458515572406],[@bibr29-1352458515572406]^ Males and females were similarly affected in this subgroup.^[@bibr17-1352458515572406],[@bibr29-1352458515572406]^ Age at disease onset appears to have a bearing on disability type. In a comparative study, Kitley et al.^[@bibr25-1352458515572406]^ found that patients in the UK had young-onset disease commonly presenting with ON and had a high risk of visual disability. An older age of onset was significantly associated with motor disability, in both Japanese and UK cohorts. Jarius et al.^[@bibr17-1352458515572406]^ have further identified distinct clinical features for NMO patients based on anti AQP4-IgG serological status. Seropositive women had more severe clinical attacks than males in this cohort, as evidenced by high lesion load in the spinal cord and other types of co-existing autoimmunity. Overall, seropositive and seronegative patients did not differ in terms of age of onset, time to relapse, relapse rates, rate of Expanded Disability Status Scale (EDSS) progression, and mortality rate. Irrespective of anti AQP4-IgG serological status, predictors of outcome included development of tetraparesis during the first attack of TM, and multiple attacks of TM in the first year. Distribution of brain lesions was different depending on anti AQP4-IgG status. Periaqueductal grey matter, hypothalamic, and area postrema lesions may be more often seen in seropositive patients.^[@bibr30-1352458515572406]^ In the Danish study, NMO-IgG seropositive patients frequently developed brainstem lesions and LETM during the decade of follow-up.^[@bibr31-1352458515572406]^ A study from Barcelona, which focused on LETM, found that EDSS at presentation was predictive of the recurrence risk and disability.^[@bibr32-1352458515572406]^

Ethnicity and disease course {#section10-1352458515572406}
============================

Ethnicity appears to be an influential factor in NMO and NMOSD. In the Cuban study^[@bibr10-1352458515572406]^ patients of African origin were older, had more relapses, abnormalities in brainstem-evoked potentials, and acquired more lesions on brain MRI than comparator patients. African Americans in the US^[@bibr18-1352458515572406]^ had significantly more brainstem MRI abnormalities than white Americans. Kitley and colleagues^[@bibr25-1352458515572406]^ compared the disease course and prognostic factors for seropositive NMO patients in the UK (*n*=59) and Japan (*n*=47). In the UK group, 45/59 were white, 12/59 were Afro-Caribbean, and two were Asian. Age of onset and ethnicity were associated with outcome. Young white patients presented with ON, and had greater visual disability. In contrast, older patients of both ethnicities presented with myelitis and greater motor disability. The Afro-Caribbean subgroup was significantly younger at onset than both white and Japanese patients (mean 28.0 ± 13.1 years and 44.9 ± 17.2 years, respectively). Initial events more commonly included those of brain/brainstem in Afro-Caribbean patients compared with white and Japanese, and uniformly had relapsing NMO compared with 80% in the other ethnicities. Annualized relapse rate among Afro-Caribbean patients was comparable with that of white patients but higher than that of the Japanese. Visual disability was more severe in non-white patients. In contrast, white patients had a later age of onset and worse motor outcomes. In the study conducted in Cuba and French West Indies,^[@bibr9-1352458515572406],[@bibr10-1352458515572406]^ lack of recovery after the first attack and a higher rate of attacks during the first year of disease were strong independent prognostic factors of mortality.

Population genetics {#section11-1352458515572406}
===================

Initial epidemiological studies have suggested ethnicity-based differences in genetics of NMO patients. However, no specific genetic determinants of NMO disease have thus far been identified. The genetic basis for these ethnic differences is not well understood, but the human leukocyte antigen (HLA) system remains an obvious candidate. Studies from Japan have analyzed the clinical and genetic features of the optico-spinal form of multiple sclerosis (OSMS), a disease entity which may overlap with NMO. In that population, conventional MS was associated with HLA-DRB1\*1501 whereas OSMS/NMO was associated with HLA DPB1\*0501.^[@bibr33-1352458515572406]^ Other population studies of HLA in NMO indicate that the DRB1\*0301^[@bibr34-1352458515572406][@bibr35-1352458515572406]--[@bibr36-1352458515572406]^ and DRB1\*10^[@bibr37-1352458515572406]^ alleles are associated with increased risk.

Familial NMO has been described. In the largest study, Matiello et al.^[@bibr38-1352458515572406]^ identified 12 families (five Asian, four Latino, two African, one white) with a total number of 25 affected individuals, 19 of whom were AQP4-IgG positive. The role of environmental influences in the etiopathogenesis of NMO has not been established. Migration studies are needed to explore whether risk is mutable with migration and how this relates to age at migration.

Insights into NMO epidemiology from the Atlas of MS Database {#section12-1352458515572406}
============================================================

In 2013, a questionnaire designed to update the MS global dataset added a number of queries relating to NMO, including prevalence, incidence, gender ratio, mean age of onset, diagnostic criteria used, and therapeutic options. This questionnaire received notifications of 10,567 cases obtained from 40 of 107 countries participating in the survey. Roughly one-third of the patients reported were from Japan (3500), creating potential bias. Data on prevalence (expressed as cases per 100,000) were available from 35 countries. In temperate zones, Central European countries had a prevalence ranging from 0.23 in Belgium to 2.0 in Norway, while Denmark (4.4) and The Netherlands (5) had comparatively high prevalence. By comparison, NMO prevalence among the Japanese population was 2.8. South Africa and Paraguay had the highest prevalence (5), followed by French West Indies (4.2). In the Middle East, the projected figures ranged from 0.16--2 and in South East Asia from 0.43--2.7. These widely disparate reports, particularly among European countries, may have resulted from differing methodologies involved in the collection of source data. No data were available from most regions of the African continent, Eastern Europe, parts of Central America, and South Asia. In each population studied patients were predominantly female, with ratios ranging from 1.0 in Ireland to 10.1 in Paraguay. Overall the mean age of onset ranged from 25.0--45.7 years. The MS database provided information from a variety of countries across the globe. In most instances, the findings were not supported by published literature and were often sourced from single or few individuals with an interest in the subject. Resource-poor countries had few neurologists and limited MRI centers, and diagnostic NMO-IgG testing was limited or non-existent. These factors hampered the reliability of the survey.

Conclusions {#section13-1352458515572406}
===========

NMO epidemiology has largely been based on relatively small populations and data from tertiary hospitals. Many of these initial studies have yielded inconsistent findings. Confounding factors include the use of non-standardized diagnostic criteria, variability in assays for anti-AQP4 antibody, inconsistent inclusion of NMO-IgG seronegative patients, small study cohorts, and potential for selection bias. These factors limit the comparative assessment and statistical power of epidemiologic studies in NMO and NMOSD. While differences in ethnicity appear to impact clinical disease course and NMO-IgG status, recent studies have disclosed similarities in incidence and prevalence of NMO. Female predominance is commonly seen and appears congruent with NMO-IgG seropositive status, which itself associates with a relapsing phenotype. HLA haplotype associations have been hypothesized, but the genetic basis for differences in risk, severity, therapeutic efficacy, or clinical outcomes remains uncertain. Larger adequately powered epidemiological studies applying standardized definitions and methodologies are needed before specific conclusions can be drawn. The advent of more specific diagnostic criteria, improved diagnostic assays and methods, and a better understanding of the basic immunology of NMO and NMOSD are likely to advance these goals. In turn, these steps should improve consistency in diagnosis and enhance study cohorts for the most informative clinical trials for NMO.
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